This course provides an in-depth exploration of cardiometabolic conditions, focusing on the latest advancements in obesity treatments and their cardiac implications. Learners will gain a clear understanding of pharmacokinetics for novel and traditional weight loss therapies, including SGLT2 inhibitors and GLP-1 agonists, and learn how to address barriers to medication access. Enhance your clinical practice by mastering the tools to manage complex cases and optimize care for patients with obesity and Type 2 diabetes.
Learning Objectives
- Describe the epidemiology, pathophysiology and history of cardiometabolic conditions
- Compare pharmacokinetics of novel and traditional obesity therapeutics which includes patients with Type 2 diabetes (SGLT2is, GLP1s and GIP/GLP-1 agonist)
- Discuss indications for novel weight loss therapies and their cardiac implications
- Explain strategies to overcome barriers to medication access
CE certificate available upon successful completion of the post-test and program evaluation.

DNP, FNP-C, FAANP, FOMA
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
Related Resources
Sorry, we couldn't find any resources.
Related Courses
Risk Assessment on the Horizon: Understanding Genetic Lipid abnormalities, screening, and treatments
1.0 CE contact hours
0.75 Pharmacology contact hours
0.75 CE contact hours
0.25 Pharmacology contact hours
Free
0.8 CE contact hours
0.8 Pharmacology contact hours
Free